• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞提取物的1H和31P核磁共振联合研究信息:药敏和耐药MCF-7人乳腺癌细胞的代谢差异

Information from combined 1H and 31P NMR studies of cell extracts: differences in metabolism between drug-sensitive and drug-resistant MCF-7 human breast cancer cells.

作者信息

Kaplan O, van Zijl P C, Cohen J S

机构信息

Medicine Branch, NCI, National Institutes of Health, Bethesda, MD 20892.

出版信息

Biochem Biophys Res Commun. 1990 Jun 15;169(2):383-90. doi: 10.1016/0006-291x(90)90343-l.

DOI:10.1016/0006-291x(90)90343-l
PMID:2357212
Abstract

Combined analysis of both 1H and 31P NMR spectra of extracts of drug-sensitive and multidrug-resistant MCF-7 human breast cancer cells enabled quantitative comparisons between the concentrations of major metabolites, as well as of their precursors. In resistant cells high energy phosphorus compounds, phosphocreatine and ATP, and also their precursors, creatine and ADP, were elevated compared to the sensitive cells. In phospholipid metabolism, the sensitive cells showed higher phosphocholine and phosphoethanolamine concentrations than the resistant cells, but choline levels were similar. These results delineated the differences in control of metabolic pathways between drug-sensitive and drug-resistant cells.

摘要

对药物敏感和多药耐药的MCF-7人乳腺癌细胞提取物的1H和31P NMR光谱进行联合分析,能够对主要代谢物及其前体的浓度进行定量比较。与敏感细胞相比,耐药细胞中的高能磷化合物、磷酸肌酸和ATP及其前体肌酸和ADP含量升高。在磷脂代谢方面,敏感细胞中的磷酸胆碱和磷酸乙醇胺浓度高于耐药细胞,但胆碱水平相似。这些结果描绘了药物敏感细胞和耐药细胞在代谢途径控制上的差异。

相似文献

1
Information from combined 1H and 31P NMR studies of cell extracts: differences in metabolism between drug-sensitive and drug-resistant MCF-7 human breast cancer cells.细胞提取物的1H和31P核磁共振联合研究信息:药敏和耐药MCF-7人乳腺癌细胞的代谢差异
Biochem Biophys Res Commun. 1990 Jun 15;169(2):383-90. doi: 10.1016/0006-291x(90)90343-l.
2
Characterization of multidrug resistance and monitoring of tumor response by combined 31P and 1H nuclear magnetic resonance spectroscopic analysis.通过联合31P和1H核磁共振波谱分析对多药耐药性进行表征及监测肿瘤反应
Anticancer Drugs. 1998 Jun;9(5):449-56. doi: 10.1097/00001813-199806000-00012.
3
NMR spectroscopy analysis of phosphorus metabolites and the effect of adriamycin on these metabolite levels in an adriamycin-sensitive and -resistant human small cell lung carcinoma cell line.磷代谢物的核磁共振光谱分析以及阿霉素对阿霉素敏感和耐药的人小细胞肺癌细胞系中这些代谢物水平的影响。
Br J Cancer. 1991 Feb;63(2):205-12. doi: 10.1038/bjc.1991.50.
4
Multinuclear NMR study of the metabolism of drug-sensitive and drug-resistant human breast cancer cells.药物敏感和耐药性人乳腺癌细胞代谢的多核核磁共振研究
Ann N Y Acad Sci. 1987;508:216-28. doi: 10.1111/j.1749-6632.1987.tb32906.x.
5
The multidrug resistance phenotype: 31P nuclear magnetic resonance characterization and 2-deoxyglucose toxicity.
Cancer Res. 1991 Mar 15;51(6):1638-44.
6
Comparison of action of the anti-neoplastic drug lonidamine on drug-sensitive and drug-resistant human breast cancer cells: 31P and 13C nuclear magnetic resonance studies.抗肿瘤药物氯尼达明对人乳腺癌敏感细胞和耐药细胞作用的比较:31P和13C核磁共振研究
Breast Cancer Res Treat. 1997 Mar;43(1):15-25. doi: 10.1023/a:1005781320906.
7
Differences in phosphate metabolite levels in drug-sensitive and -resistant human breast cancer cell lines determined by 31P magnetic resonance spectroscopy.通过31P磁共振波谱法测定的药物敏感和耐药人乳腺癌细胞系中磷酸代谢物水平的差异。
Cancer Res. 1986 Aug;46(8):4087-90.
8
Levels of phospholipid metabolites in breast cancer cells treated with antimitotic drugs: a 31P-magnetic resonance spectroscopy study.抗有丝分裂药物处理的乳腺癌细胞中磷脂代谢物水平:一项31P磁共振波谱研究。
Cancer Res. 2001 Oct 15;61(20):7536-43.
9
Variations in energy and phospholipid metabolism in normal and cancer human mammary epithelial cells.正常与癌性人乳腺上皮细胞中能量和磷脂代谢的变化
Anticancer Res. 1996 May-Jun;16(3B):1381-8.
10
Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: toxicity and magnetic resonance spectroscopy studies of metabolism.2-脱氧葡萄糖对人乳腺癌药敏细胞和耐药细胞的影响:代谢毒性及磁共振波谱研究
Cancer Res. 1990 Feb 1;50(3):544-51.

引用本文的文献

1
Phosphatidylcholine-Derived Lipid Mediators: The Crosstalk Between Cancer Cells and Immune Cells.磷脂酰胆碱衍生的脂质介质:癌细胞与免疫细胞的串扰。
Front Immunol. 2022 Feb 15;13:768606. doi: 10.3389/fimmu.2022.768606. eCollection 2022.
2
NMR as a "Gold Standard" Method in Drug Design and Discovery.NMR 作为药物设计和发现的“金标准”方法。
Molecules. 2020 Oct 9;25(20):4597. doi: 10.3390/molecules25204597.
3
NMR Spectroscopy for Metabolomics Research.用于代谢组学研究的核磁共振光谱法
Metabolites. 2019 Jun 27;9(7):123. doi: 10.3390/metabo9070123.
4
Common-mode differential-mode (CMDM) method for double-nuclear MR signal excitation and reception at ultrahigh fields.超高场下双核磁共振信号激发与接收的共模差模(CMDM)方法。
IEEE Trans Med Imaging. 2011 Nov;30(11):1965-73. doi: 10.1109/TMI.2011.2160192. Epub 2011 Jun 20.
5
Metabolic assessment of a novel chronic myelogenous leukemic cell line and an imatinib resistant subline by H NMR spectroscopy.通过核磁共振氢谱对一种新型慢性粒细胞白血病细胞系及伊马替尼耐药亚系进行代谢评估。
Metabolomics. 2010 Sep;6(3):439-450. doi: 10.1007/s11306-010-0204-0. Epub 2010 Mar 23.
6
Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells.伊马替尼耐药慢性髓系白血病细胞的代谢特征。
Br J Pharmacol. 2009 Sep;158(2):588-600. doi: 10.1111/j.1476-5381.2009.00345.x. Epub 2009 Aug 6.
7
Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death.2-脱氧-D-葡萄糖作为一种化疗药物的评估:细胞死亡机制
Br J Cancer. 2002 Sep 23;87(7):805-12. doi: 10.1038/sj.bjc.6600547.
8
HGF/SF activates glycolysis and oxidative phosphorylation in DA3 murine mammary cancer cells.肝细胞生长因子/散射因子激活DA3小鼠乳腺癌细胞中的糖酵解和氧化磷酸化。
Neoplasia. 2000 Jul-Aug;2(4):365-77. doi: 10.1038/sj.neo.7900103.
9
Metabolism of breast cancer cells as revealed by non-invasive magnetic resonance spectroscopy studies.
Breast Cancer Res Treat. 1994;31(2-3):285-99. doi: 10.1007/BF00666161.
10
Hormone dependence of breast cancer cells and the effects of tamoxifen and estrogen: 31P NMR studies.
Breast Cancer Res Treat. 1995 Mar;33(3):209-17. doi: 10.1007/BF00665945.